These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34986666)

  • 21. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
    Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
    J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
    Martin A; Lavoie L; Goetghebeur M; Schellenberg R
    Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuts and Bolts of Subcutaneous Therapy.
    Duff C; Ballow M
    Immunol Allergy Clin North Am; 2020 Aug; 40(3):527-537. PubMed ID: 32654697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
    Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
    Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
    Chen Y; Wang C; Xu F; Ming F; Zhang H
    Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
    Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
    J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
    Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
    PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.
    Gonzalez JM; Ballow M; Fairchild A; Runken MC
    Front Immunol; 2022; 13():827305. PubMed ID: 35185918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).
    Knutsen AP; Leiva LE; Caruthers C; Rodrigues J; Sorensen RU
    Clin Exp Immunol; 2015 Oct; 182(1):51-6. PubMed ID: 26230522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.
    Kan AKC; Leung GMK; Chiang V; Au EYL; Lau CS; Li PH
    Front Immunol; 2022; 13():984110. PubMed ID: 36591300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
    Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
    Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.